CD4-positive T-cell primary central nervous system lymphoma in an HIV positive patient

American Journal of Clinical Pathology

Volumn 145, Issue 2, 2016, Pages 258-265

  Nael, Ali ^a   Walavalkar, Vighnesh ^a   Wu, William ^b   Nael, Kambiz ^c   Kim, Ronald ^a   Rezk, Sherif ^a   Zhao, Xiaohui ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^c UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

CD4 positive T cell lymphoma; EBV; HIV; Primary central nervous system lymphoma

Indexed keywords

LATENT MEMBRANE PROTEIN 1; METHOTREXATE; T LYMPHOCYTE RECEPTOR; VIRUS DNA;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; B CELL LYMPHOMA; BRAIN BIOPSY; BRAIN HISTOLOGY; BRAIN RADIATION; CASE REPORT; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CEREBROSPINAL FLUID CYTOLOGY; FEMALE; FLOW CYTOMETRY; GENE REARRANGEMENT; HEMISPHERE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LETHARGY; MACROCYTIC ANEMIA; MEDICAL HISTORY; MIDDLE AGED; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA; PRIORITY JOURNAL; PYREXIA IDIOPATHICA; T CELL LYMPHOMA; T LYMPHOCYTE RECEPTOR GENE; VIRUS LOAD; WEAKNESS; WHITE MATTER; BIOPSY; CENTRAL NERVOUS SYSTEM NEOPLASMS; COMPLICATION; EPSTEIN BARR VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ISOLATION AND PURIFICATION; LYMPHOMA, AIDS-RELATED; LYMPHOMA, T-CELL; PATHOLOGY; VIROLOGY;

BIOPSY; CD4-POSITIVE T-LYMPHOCYTES; CENTRAL NERVOUS SYSTEM NEOPLASMS; DNA, VIRAL; FEMALE; HERPESVIRUS 4, HUMAN; HIV SEROPOSITIVITY; HUMANS; LYMPHOMA, AIDS-RELATED; LYMPHOMA, T-CELL; MIDDLE AGED;

EID: 84959318126     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1093/AJCP/AQV087     Document Type: Article

References (43)

1. Flinn IW, Ambinder RF. AIDS primary central nervous system lymphoma. Curr Opin Oncol. 1996;8:373-376.
2. Knowles DM, Pirog EC. Pathology of AIDS-related lymph-omas and other AIDS-defining neoplasms. Eur J Cancer. 2001;37:1236-1250.
3. Petrara MR, Freguja R, Gianesin K, et al. Epstein-Barr virus-driven lymphomagenesis in the context of human immunodeficiency virus type 1 infection. Front Microbiol. 2013;4:311.
4. Latta S, Myint ZW, Jallad B, et al. Primary central nervous system T-cell lymphoma in aids patients: case report and literature review. Curr Oncol. 2010;17:63-66.
5. Manenti G, Di Giuliano F, Bindi A, et al. A Case of primary T-cell central nervous system lymphoma: MR imaging and MR spectroscopy assessment. Case Rep Radiol. 2013;2013:916348.
6. Bindal AK, Blisard KS, Melin-Aldama H, et al. Primary T-cell lymphoma of the brain in acquired immunodeficiency syndrome: case report. J Neurooncol. 1997;31:267-271.
7. Aydin F, Bartholomew PM, Vinson DG. Primary T-cell lymphoma of the brain in a patient at advanced stage of acquired immunodeficiency syndrome. Arch Pathol Lab Med. 1998;122:361-365.
8. Cobo F, Talavera P, Busquier H, et al. CNK/T-cell brain lymphoma associated with Epstein-Barr virus in a patient with AIDS. Neuropathology. 2007;27:396-402.
9. Rao CWM, Koszlowski PB, Anzil AP, et al. Primary T cell central nervous system lymphoma in AIDS [abstract]. J Neuropathol Exp Neurol. 1989;48:302.
10. Smith GH, MacLeod JD, Routy JP. Primary brain T-cell lymphoma in an AIDS patient [abstract 4225]. Int Conf AIDS. 1996;11:289.
11. Raphael MSJ, Borisch B, Cesarman E, et al. Lymphoma associated with HIV infection. In: Swerdlow SH, Campo E, Harris NL, et al, eds. WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon, France: IARC; 2008:340-342.
12. Simard EP, Pfeiffer RM, Engels EA. Cumulative incidence of cancer among individuals with acquired immunodeficiency syndrome in the United States. Cancer. 2011;117:1089-1096.
13. Rios A. HIV-related hematological malignancies: a concise review. Clin Lymphoma Myeloma Leuk. 2014;14S:S96-S103.
14. Hoffmann C, Hentrich M, Gillor D, et al. Hodgkin lymph-oma is as common as non-Hodgkin lymphoma in HIV-positive patients with sustained viral suppression and limited immune deficiency: a prospective cohort study. HIV Med. 2014;16:261-264.
15. Caceres W, Cruz-Amy M, Diaz-Melendez V. AIDS-related malignancies: revisited. P R Health Sci J. 2010;29:70-75.
16. Franceschi S, Lise M, Clifford GM, et al. Changing patterns of cancer incidence in the early-and late-HAART periods: the Swiss HIV Cohort Study. Br J Cancer. 2010;103:416-422.
17. Jacobson CA, Abramson JS. HIV-associated Hodgkin's lymphoma: prognosis and therapy in the era of cART. Adv Hematol. 2012;2012:507257.
18. Castillo JJ, Beltran BE, Bibas M, et al. Prognostic factors in patients with HIV-associated peripheral T-cell lymphoma: a multicenter study. Am J Hematol. 2011;86:256-261.
19. Herndier BG, Shiramizu BT, Jewett NE, et al. Acquired immunodeficiency syndrome-associated T-cell lymph-oma: evidence for human immunodeficiency virus type 1-associated T-cell transformation. Blood. 1992;79:1768-1774.
20. Wu W, Youm W, Rezk SA, et al. Human herpesvirus 8-unrelated primary effusion lymphoma-like lymphoma: report of a rare case and review of 54 cases in the literature. Am J Clin Pathol. 2013;140:258-273.
21. O'Neill BP, Decker PA, Tieu C, et al. The changing incidence of primary central nervous system lymphoma is driven primarily by the changing incidence in young and middle-aged men and differs from time trends in systemic diffuse large B-cell non-Hodgkin's lymphoma. Am J Hematol. 2013;88:997-1000.
22. Cavaliere R, Petroni G, Lopes MB, et al; International Primary Central Nervous System Lymphoma Collaborative Group. Primary central nervous system post-transplantation lymphoproliferative disorder: an International Primary Central Nervous System Lymphoma Collaborative Group Report. Cancer. 2010;116:863-870.
23. Kluin PM, Deckert M, Ferry JA. Primary diffuse large B-cell lymphoma of the CNS. In: SH Swerdlow, E Campo, NL Harris, et al, eds. WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon, France: IARC; 2008;1:240-241.
24. Corcoran C, Rebe K, van der Plas H, et al. The predictive value of cerebrospinal fluid Epstein-Barr viral load as a marker of primary central nervous system lymphoma in HIV-infected persons. J Clin Virol. 2008;42:433-436.
25. Gonzalez-Aguilar A, Soto-Hernandez JL. The management of primary central nervous system lymphoma related to AIDS in the HAART era. Curr Opin Oncol. 2011;23:648-653.
26. Graber JJ, Omuro A. Primary central nervous system lymph-oma: is there still a role for radiotherapy? Curr Opin Neurol. 2011;24:633-640.
27. Gerard LM, Imrie KR, Mangel J, et al. High-dose methotrex-ate based chemotherapy with deferred radiation for treatment of newly diagnosed primary central nervous system lymphoma. Leuk Lymphoma. 2011;52:1882-1890.
28. Uldrick TS, Pipkin S, Scheer S, et al. Factors associated with survival among patients with AIDS-related primary central nervous system lymphoma. AIDS. 2014;28:397-405.
29. Engels EA, Pfeiffer RM, Landgren O, et al. Immunologic and virologic predictors of AIDS-related non-Hodgkin lymph-oma in the highly active antiretroviral therapy era. J Acquir Immune Defic Syndr. 2010;54:78-84.
30. Breen EC, Hussain SK, Magpantay L, et al. B-cell stimulatory cytokines and markers of immune activation are elevated several years prior to the diagnosis of systemic AIDS-associated non-Hodgkin B-cell lymphoma. Cancer Epidemiol Biomarkers Prev. 2011;20:1303-1314.
31. Shiramizu B, Herndier BG, McGrath MS. Identification of a common clonal human immunodeficiency virus integration site in human immunodeficiency virus-associated lymph-omas. Cancer Res. 1994;54:2069-2072.
32. Shiramizu B, Herndier B, Abby H, et al. Clonal HIV is present in a wide variety of HIV-associated malignancies and cell separation studies map the clone to tumor-associated macrophages. J Acquir Immune Defic Syndr Hum Retrovirol. 1997;14:A50-A135.
33. Brenchley JM, Price DA, Schacker TW, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med. 2006;12:1365-1371.
34. Marks MA, Rabkin CS, Engels EA, et al. Markers of micro-bial translocation and risk of AIDS-related lymphoma. AIDS. 2013;27:469-474.
35. Giagulli C, Marsico S, Magiera AK, et al. Opposite effects of HIV-1 p17 variants on PTEN activation and cell growth in B cells. PLoS One. 2011;6:e17831.
36. Rezk SA, Weiss LM. Epstein-Barr virus-associated lym-phoproliferative disorders. Hum Pathol. 2007;38:1293-1304.
37. Rickinson A. Epstein-Barr virus. Virus Res. 2002;82:109-113.
38. Coleman CB, Wohlford EM, Smith NA, et al. Epstein-Barr virus type 2 latently infects T-cells inducing an atypical activation characterized by expression of lymphotactic cyto-kines. J Virol. 2014;89:2301-2312.
39. Chen MR. Epstein-Barr virus, the immune system, and associated diseases. Front Microbiol. 2011;2:5.
40. Terrin L, Dal Col J, Rampazzo E, et al. Latent membrane protein 1 of Epstein-Barr virus activates the hTERT promoter and enhances telomerase activity in B lymphocytes. J Virol. 2008;82:10175-10187.
41. Giunco S, Dolcetti R, Keppel S, et al. hTERT inhibition triggers Epstein-Barr virus lytic cycle and apoptosis in immortalized and transformed B cells: a basis for new therapies. Clin Cancer Res. 2013;19:2036-2047.
42. Gasser O, Bihl FK, Wolbers M, et al. HIV patients developing primary CNS lymphoma lack EBV-specific CD41/2 T cell function irrespective of absolute CD41/2 T cell counts. PLoS Med. 2007;4:e96.
43. Petrara MR, Cattelan AM, Zanchetta M, et al. Epstein-Barr virus load and immune activation in human immunodeficiency virus type 1-infected patients. J Clin Virol. 2012;53:195-200.